Cellebrite DI Ltd. (NASDAQ:CLBT) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have earned a consensus rating of “Moderate Buy” from the five research firms that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $22.50.

A number of analysts have recently commented on CLBT shares. Wall Street Zen upgraded Cellebrite DI from a “sell” rating to a “hold” rating in a research note on Sunday, March 15th. Needham & Company LLC reduced their price target on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Cellebrite DI in a report on Monday, December 29th.

Institutional Trading of Cellebrite DI

A number of hedge funds have recently added to or reduced their stakes in the company. Cooper Creek Partners Management LLC purchased a new stake in shares of Cellebrite DI during the 3rd quarter worth about $55,999,000. Granahan Investment Management LLC increased its stake in shares of Cellebrite DI by 1,108.5% in the 3rd quarter. Granahan Investment Management LLC now owns 2,629,299 shares of the company’s stock valued at $48,721,000 after purchasing an additional 2,411,726 shares in the last quarter. Capital International Investors acquired a new position in Cellebrite DI in the 4th quarter worth about $41,073,000. Invesco Ltd. raised its holdings in Cellebrite DI by 58.6% in the 3rd quarter. Invesco Ltd. now owns 5,560,196 shares of the company’s stock worth $103,030,000 after purchasing an additional 2,054,644 shares during the period. Finally, Pertento Partners LLP boosted its position in Cellebrite DI by 57.8% during the third quarter. Pertento Partners LLP now owns 4,648,215 shares of the company’s stock worth $86,131,000 after purchasing an additional 1,702,574 shares in the last quarter. 45.88% of the stock is owned by hedge funds and other institutional investors.

Cellebrite DI Price Performance

NASDAQ CLBT opened at $13.88 on Thursday. Cellebrite DI has a 1 year low of $11.76 and a 1 year high of $20.53. The company has a market capitalization of $3.46 billion, a PE ratio of 44.77, a P/E/G ratio of 2.11 and a beta of 1.27. The company has a fifty day moving average of $14.36 and a 200 day moving average of $16.67.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share for the quarter, hitting the consensus estimate of $0.14. The company had revenue of $128.82 million for the quarter, compared to the consensus estimate of $126.07 million. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The firm’s revenue for the quarter was up 28.8% compared to the same quarter last year. During the same period last year, the firm earned $0.10 EPS. Research analysts expect that Cellebrite DI will post 0.3 earnings per share for the current year.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.